Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…

Source: Endpoints News